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Chlamydia trachomatis is a Gram-negative obligate intracellular bacterium. It is the leading cause of bacterial sexual transmitted
infections (STIs). World Health Organization figures estimated that over 90 million new cases of genital C. trachomatis infections
occur worldwide each year. A vaccination program is considered to be the best approach to reduce the prevalence ofC. trachomatis
infections, as it would be much cheaper and have a greater impact on controlling C. trachomatis infections worldwide rather than
a screening program or treating infections with antibiotics. Currently, there are no vaccines available which eﬀectively protect
against a C. trachomatis genital infection despite the many eﬀorts that have been made throughout the years. In this paper, the
many attempts to develop a protective vaccine against a genital C. trachomatis infection will be reviewed.
1. Introduction
Chlamydia trachomatis is a Gram-negative obligate intracel-
lular bacterium. It is the leading cause of bacterial sexu-
ally transmitted disease in both developed and developing
countries with more than 90 million new cases of genital C.
trachomatis infections occurring each year [1]. In the past
years, an increase in the number of STIs and in particular
ofC. trachomatis infections has been observed inmany, if not
all, European countries [2]. This increase might be attributed
to changes in attitudes, increased awareness of healthcare
workers, and improved diagnostics.
In the genital tract, infection with C. trachomatis is
propagated within the single cell columnar layer of the
epithelium in the urethra of men and the endocervix of
women. Within the epithelial cells, C. trachomatis undergoes
a unique biphasic developmental cycle consisting of an
infectious, but metabolically inert, elementary body (EB)
and a noninfectious, but metabolically active, reticulate body
(RB). After completion of the developmental cycle, the EBs
are released and infect neighboring epithelial cells, thereby
spreading the infection.
Infection can result in acute inflammation characterized
by redness, edema, and mucosal discharge and is diagnosed
clinically as mucopurulent cervicitis in women and non-
gonococcal urethritis in men [3, 4]. In women, infection
canmanifest as abnormal vaginal discharge and/or postcoital
bleeding, while the infection is limited to the lower genital
tract and irregular uterine bleeding and/or pelvic discomfort
once the infection ascends to the upper genital tract [4].
Symptoms inmales are generally limited to dysuria andmod-
erate clear to whitish discharge [4]. While these symptoms
signify an infection, the absence of such symptoms does not
necessarily indicate the absence of infection. Up to 75% of
women and 50% of men infected with C. trachomatis are
asymptomatic [5, 6], and these infected people do not seek
medical attention. If the infection remains untreated, it often
results in pelvic inflammatory disease (PID), tubal scarring,
ectopic pregnancy, and chronic pelvic pain in women which
could lead to infertility, epididymitis in men, and infant
pneumonia in children [7–10].
Although very eﬀective antimicrobial therapy is available,
a vaccination program is considered to be the best approach
to reduce the prevalence of C. trachomatis infections. It
would be much cheaper and have a greater impact on con-
trolling C. trachomatis infections worldwide than a screening
program or treating infections with antibiotics. Long-term
induced immunity against STIs such as C. trachomatis
would be preferable. However, since STIs have the highest
incidence at the reproductive age, even short- to medium-
term immunity would be of great benefit. Therefore, a C.
trachomatis vaccine protecting at least women in their fertile
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period against complications would be a valuable tool in
achieving a higher level of public health. Currently, there
are no vaccines available against a C. trachomatis genital
infection despite the many eﬀorts that have been made
throughout the years to develop a protective C. trachomatis
vaccine. In this paper the many attempts to develop a
protective vaccine against a genital C. trachomatis infection
will be reviewed.
2. Chlamydia muridarum versus
C. trachomatis MouseModels
The most used animal model to study C. trachomatis female
tract infections is the mouse model. The mouse is susceptible
to C. muridarum mouse pneumonitis (MoPn), formerly
known as the mouse biovar of C. trachomatis, and to human
genital tract isolates of C. trachomatis. The genomes of these
species share remarkable similarities in the content and order
of genes and in the presence of putative virulence factors
[11]. An important diﬀerence between the species is the
absence and presence of a tryptophan operon in the genome
of C. trachomatis and C. muridarum, respectively [12, 13].
Consequently, these biovars have diﬀerential sensitivity to
IFN-γ, a cytokine which plays an important role in the early
clearance of chlamydia from the genital tract [14].Most likely
the C. muridarum and the C. trachomatis strain will also
diﬀer in response to other cytokines.
There are also significant diﬀerences in virulence charac-
teristics among both biovars. In contrast to human isolates,
C. muridarum is able to cause severe upper genital tract
pathology and a high incidence of infertility after a single
infection in mice [15]. In addition, the developmental
cycle of C. muridarum is more rapid, its duration being
approximately half that of human strains, and the strain
is more prolific. Chlamydia muridarum can infect mice
of various strains nearly equally, while infection of mice
with C. trachomatis is highly dependable on the mouse
strain. Overall, lower shedding and minimal to moderate
inflammation can be noticed in mice infected with C.
trachomatis. Furthermore, postinfection sequelae are less
common. This is in accordance to the fact that upper genital
tract progression followed by pathology, usually resulting
from multiple infections, is only seen in a small percentage
of women [16].
In contrast to C. muridarum infection, C. trachomatis
infection was unaltered in the absence of CD4+ T cells. Mice
infected with C. trachomatis developed protective immunity
to rechallenge, but unlike C. muridarum infection, optimum
resistance required multiple infectious challenges despite the
generation of adaptive serum and local chlamydial specific
immune responses. Thus, understanding the chlamydial
pathogenic and host immunologic factors that result in a
diminished protective role for CD4+ T cells in C. trachomatis
murine infection might lead to new insights important to
human immunity and vaccine development [17]. It has
been demonstrated that strong adaptive immune responses
are generated when mice are infected with C. trachomatis
serovars [3, 18, 19], but it has also been shown that these
infections in mice can resolve in the absence of adaptive
immunity, suggesting that innate immune responses alone
can resolve infection [13]. This is not necessarily a reason
to invalidate the use of C. trachomatis serovars in murine
studies of genital tract infection or in vaccine development.
It could be that the rather mild infection seen in murine
studies utilizing human C. trachomatis biovars may replicate
some aspects of human infection. In order to resolve the
murineC. muridarum genital infection and to protect against
reinfection, adaptive immune responses are absolutely indis-
pensable.
As there are considerable diﬀerences between the C.
muridarum and the C. trachomatis murine model, it is
diﬃcult to make direct comparisons. In order to understand
the pathogenesis of human chlamydial infections completely,
it is absolutely necessary to thoroughly investigate chlamydial
infection in its natural human host [20].
3. Protective Immune Responses to
C. trachomatis
Information on the immune mechanisms of clearance of
infection and resistance to reinfection has been provided
in particular by mouse models of genital infection. T cells,
especially major histocompatibility complex (MHC) class II-
restricted CD4+ T cells, are required for protective immunity
[21–24]. MHC class I-restricted CD8+ T cells, on the other
hand, are not necessary for infection resolution or immunity
to reinfection [21–24]. The protective role of antibody is
less easily discernible than that of the cellular response, but
important to vaccine development, it is as protective as CD4+
T cells in immunity to reinfection [22, 25]. Furthermore,
Th1 cytokines, specifically IFN-γ and interleukin-12 (IL-12),
are essential to induce a protective response [13, 26, 27].
In women, CD4+ T cells are indeed recruited to the cervix
during active infection; however, CD8+ and dentritic cells
are also recruited, and the relative proportions of these
cells may be situational. Diﬀerent studies involving women
have confirmed that local Th1 cytokines, mainly IFN-γ, are
associated with C. trachomatis infection (reviewed by [28])
although these studies have not been able to determine
which specific responses lead to infection resolution versus
persistence [29–31]. Serum and genital mucosal IgG and
IgA antibodies to specific C. trachomatis proteins and to
chlamydial EBs are usually detected during active infection
in women [32–34]. These antibody responses in humans
infected with C. trachomatis, including those measured in
endocervical secretions, have not been found to correlate
with protective immunity but appear to be markers of prior
infection.
When developing a vaccine against genital C. trachomatis
infections, it is important to take into account the unique
properties of the genital tract. This mucosal site is unique
among mucosal eﬀector tissues, as it lacks organized lym-
phatics which can result in a delayed systemic response
relative to other sites [35]. Furthermore, the female genital
tract is also subjected to hormonal regulation, and the
eﬀectiveness of intravaginal vaccination has been shown to
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be influenced by the phase of the menstrual cycle [35–37].
The immunological characteristics of the genital tract and
the tropism of chlamydia for mucosal epithelial cells show
that a C. trachomatis vaccine has to induce both mucosal and
systemic protective responses.
4.Whole OrganismVaccines—First-Generation
C. trachomatis Vaccines
Initial attempts to develop an eﬀective vaccine for controlling
both animal and human chlamydial infections began with
the use of inactivated or live, attenuated whole organism
preparations in the 1950s. These vaccines can oﬀer a degree
of protection but are far from ideal. Common problems are
the cost and the complexity of production, the requirement
for cold storage, the presence of antigens which can induce
autoimmunity or immunopathology, and the limited eﬃcacy
in neonates with high levels of maternal antibodies [38].
4.1. Live Attenuated Organisms. The first vaccines that were
used against Chlamydiaceae were live vaccines. With this
method of immunization, attenuated or modified living
chlamydial organisms were used. The development of atten-
uated strains usually happens by a number of passages
of the wild-type strain in diﬀerent types of cell cultures
or by chemical mutagenesis. Due to the passages, one or
more mutations could arise, resulting in a nonvirulent
attenuated strain. Live attenuated vaccines can elicit humoral
and cellular immunity, because they replicate in a manner
analogous to the target pathogen, promoting the processing
and presentation of antigens in a way that is most similar to
the natural infection [39]. On the other hand, they can also
revert to the virulent wild-type strain resulting in disease or
persistent infection. Whole-organism vaccination is unlikely
to be attempted in the near future, because there is a risk
of immunopathology, the large-scale production of pure
chlamydiae is extremely diﬃcult [40] and because of the
possible spread of live Chlamydiaceae in the environment
[41].
In the 1960s, unsuccessful vaccination trials with live
attenuated vaccines against trachoma were performed in
humans and primates [42]. Four decades later, several
authors have explored the possibility to vaccinate with live
attenuated bacteria against genital C. trachomatis infection.
Peterson et al. [43] immunized mice intranasally or
intraperitoneally with viable C. trachomatis, serovar E. Mice
immunized intranasally with live C. trachomatis exhib-
ited significant protection upon a vaginal infection, while
intraperitoneally immunized mice did not. However, the
protection was not complete. Su et al. [44] performed an
experiment in mice to investigate the ability of a live atten-
uated C. trachomatis vaccine to prevent genital infection.
Mice were treated with a subchlamydiacidal concentration of
oxytetracycline following vaginal infection. Results showed
that a self-limiting subclinical infection of the murine genital
tract with C. trachomatis is as eﬃcient as a clinically apparent
acute infection in generating a protective anti-chlamydial
immune response. Based on these results, the authors
concluded that a live attenuated vaccine would be useful
for the prevention of chlamydial STIs. Recently, Olivares-
Zavaleta et al. [45] evaluated the protective immunity of the
attenuated C. trachomatis L2 (25667R) strain in a murine
model. They concluded that intravaginal vaccination with
the live-attenuated strain L2 is safe, induces a systemic
antibody and a CD4+ Th1-based immune response, but its
protective eﬃcacy is limited to reducing chlamydial burden
at early time periods after-infection.
Recently, Yu et al. [46] vaccinated mice intranasally
with live C. muridarum with or without CpG-containing
oligodeoxynucleotide 1862. Immunization elicited widely
disparate levels of protective immunity to genital tract
challenge. Protection was correlated with the frequency of
multifunctional T cells coexpressing IFN-γ and TNF-α with
or without IL-2. These results suggest that IFN-γ producing
CD4+ T cells that highly coexpress TNF- α may be the
optimal eﬀector cells for protective immunity.
In view of the safety aspects (possible return to the
virulent wild type strain) and the risk for immunopatho-
logical damage, it seems unlikely that a live attenuated C.
trachomatis vaccine will be allowed in humans.
4.2. Inactivated or Killed Organisms. Because live vaccines
are not always safe or available, research switched to the
use of killed or inactivated organisms. Inactivation was
done by heat or chemical treatment. Compared to live
organisms, inactivated or killed vaccines also have some
disadvantages. They may contain undesirable components
like bacterial endotoxins, that can cause detrimental side
eﬀects, or nonprotective components that may reduce the
degree of protection that is required. Their major disad-
vantage is that they are not able to replicate anymore,
which stresses the need to revaccinate and to use adjuvants.
Another consequence of their inability to replicate is that
they are poor inducers of cell-mediated immunity although
they can induce and adequate level of humoral immunity
[38]. Because a strong cell-mediated immunity is needed
for clearance of chlamydial infections, inactivated or killed
organisms seem to be less suitable for vaccine development
against Chlamydiaceae.
Studies on inactivated or killed organism vaccines against
genital C. trachomatis infection are rare. In this study, Peter-
son et al. [43] failed to elicit a protective response to a vaginal
C. trachomatis infection in mice immunized intranasally
and intraperitoneally with 1 × 106 UV inactivated inclusion
forming units of C. trachomatis serovar E.
5. Subunit Vaccines—Second-Generation
C. trachomatis Vaccines
In order to avoid harmful eﬀect of the preparations con-
taining the whole organism, it was proposed that a subunit
vaccine was needed. Subunit vaccines are safer, they cannot
revert to a virulent form, and undesirable antigens, which
can induce immunopathology or inflammatory damage, can
be avoided [47]. Vaccine candidate antigens, or parts of anti-
gens, may be represented as purified proteins, recombinant
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proteins or as synthetic proteins [48]. But subunit vaccines
have also some disadvantages. Like inactivated vaccines, they
are poor inducers of cell-mediated immunity [38], which is
very important in the defense against chlamydial infections.
Furthermore, the use of adjuvants is being recommended.
5.1. Purified MOMP and COMC Preparations. Following
the identification of the major outer membrane protein
(MOMP) as the structurally and immunologically dominant
protein in the chlamydial outer membrane [49], vaccine
research mainly focused on this protein. Some results were
encouraging while others rather disappointing. Pal et al. [50]
found that a chlamydial outer membrane complex (COMC)
preparation of C. muridarum could induce significantly pro-
tective immunity in mice against a genital challenge, while
purified MOMP preparations could not. Some years later,
the same research group immunized mice with a purified
and refolded preparation of the C. muridarum MOMP in
combination with Freund’s adjuvants. A significant level of
protection was conferred in the vaccinated mice against a
genital challenge [51]. Cheng et al. [52] demonstrated the
protective potential of native MOMP of a C. muridarum
serovar in combination with novel adjuvants, the nontoxic
subunit B of cholera toxin (CTB-CpG). Immunization
elicited a significant antigen-specific antibody and cell-
mediated immune response as well as protection against a
pulmonary challenge with C. muridarum. Cunningham et
al. [53] could demonstrate that immunization of mice with
purified C. muridarum MOMP could induce neutralizing
antibodies which leaded to reduced numbers of infected
mice. Surprisingly, these antibodies also accelerated the
development of severe oviduct pathology. Therefore, it is
important to keep in mind that immunity can potentially
induce pathology and this should be considered when
designing vaccines.
Igietseme and Murdin [54] prepared a MOMP-ISCOM
vaccine based on MOMP extracted from C. trachomatis
serovar D. This vaccine was able to produce a Th1 antigen-
specific immune response, and immunized mice cleared a
vaginal infection within one week.
From these studies, it is clear that some preparations can
induce more protection than others. This is probably due to
the diﬀerence in extraction method which can influence the
preservation of conformational MOMP epitopes, necessary
for protection. Although vaccination with refolded, purified
MOMP preparations have been reasonable successful, the
major drawbacks of these vaccines are that they are very
expensive and there are problems to grow chlamydia in bulk,
which renders these kinds of vaccines commercially non-
viable [42].
5.2. Recombinant Proteins. Nowadays, it is possible to pro-
duce high amounts of bacterial proteins by recombinant
DNA technology which is cheaper and more cost eﬀective.
The genes, coding for protective antigens, will be expressed in
prokaryotic or eukaryotic cells that will produce the desired
recombinant protein. For chlamydial vaccines, recombinant
MOMP (rMOMP) is generally used. However, the expression
of full-length rMOMP in prokaryotic expression systems is
generally toxic, and it is also diﬃcult to produce rMOMP in
a native form with intact, conformationally relevant epitopes
[55]. Moreover, the chlamydial MOMP is glycosylated [56,
57].
Diﬀerent attempts were made to elicit protection against
a C. trachomatis infection by rMOMP vaccination. Transcu-
taneous immunization with MOMP in combination with the
cholera toxin and CpG oligodeoxynucleotides elicits IgG and
IgA antibody response in the vaginal and cervical lavage fluid
and an IgG antibody response in the serum. Furthermore,
IFN-γ secreting T cells were activated in the draining lymph
nodes. The immunization protocol resulted in enhanced
clearance of C. muridarum following intravaginal challenge
of mice [58]. Pal et al. [59] demonstrated that immunisa-
tion with purified C. muridarum MOMP, co-administered
with Borrelia burgdorferi Outer surface protein (Osp) A as
adjuvant, can induce significant protection in mice against
a C. muridarum genital infection. Sun et al. [60] com-
pared vaccines based on recombinant (rMOMP) and native
MOMP (nMOMP). The recombinant preparation based
on C. muridarum MOMP can elicit a protective immune
response in mice against an intranasal challenge. However,
the degree of protection obtained with the rMOMP was
not as robust as that achieved with an nMOMP preparation
indicating that the structural conformation of the MOMP is
important for inducing protection. Hickey et al. [61] showed
that transcutaneous immunization of mice with rMOMP
incorporated in lipid C, induces partial protection of both
the respiratory and genital mucosae against challenge with
C. muridarum. The eﬃcacy of a recombinant vaccine is not
only defined by the protein that is used but also by the
administration routes. It has been proven that a combined
systemic and mucosal vaccination with rMOMP provides
better protection against a challenge with C. muridarum
than either systemic or mucosal immunization alone [62].
Systemic immunization of mice with rMOMP from C.
trachomatis could reduce the number of animals developing
severe salpingitis but failed to reduce chlamydial colonization
of the lower genital tract. Mice, immunized with rMOMP
directly into the Peyer’s patches (to stimulate mucosal
immunity), shed fewer chlamydiae from the vagina, but
showed little reduction in oviduct damage. Furthermore,
the number of animals developing severe salpingitis could
not be reduced. Although in both cases specific IgG and
IgA antibody responses could be observed, they could not
completely protect the mice [63].
Although most recombinant vaccines are based on
MOMP, other proteins can also be viable vaccine candidates.
In 2007, a novel vaccination strategy using a secreted
protein, chlamydial protease-like activity factor (CPAF) was
developed by Murthy et al. [64]. Intranasal immuniza-
tion using recombinant CPAF (rCPAF) accompanied by
interleukin-12 (IL-12) was used to assess the protective
immunity against genital C. muridarum infection in BALB/c
mice. rCPAF + IL-12-vaccinated mice displayed significantly
reduced bacterial shedding upon chlamydial challenge and
accelerated resolution of infection compared to mock-
immunized animals. Moreover, rCPAF+ IL-12-immunized
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animals exhibited protection against pathological conse-
quences of chlamydial infection. These results demonstrate
for the first time that a secreted chlamydial protein, CPAF,
is a viable vaccine candidate that should be considered
for induction of eﬃcacious, antichlamydial immunity. The
chlamydial proteins OmcB and rl16 have been identified as
human B and T cell targets during chlamydial infections
in humans [65, 66]. Vaccination of mice with a fusion
protein (CTH1) composed of those two antigens promoted a
CD4+ T-cell dependent protective response but lacks a CD4
independent protective mechanism for complete protection
[67].
5.3. Synthetic Peptides. Today, computer-based methods to
predict antigenic domains or epitopes are available. Synthetic
production of these epitopes makes it possible to produce
synthetic peptides which correspond with the important
immunogenic domains on the antigens. On the other hand,
we have to take into account that a lot of antigenic determi-
nants need conformational or three-dimensional structures,
like in the complete protein, to elicit an immune response.
Studies with MOMP peptides and oligopeptide vaccines
showed variable results with maximum partial protection.
Preliminary studies in mice indicated that intradermal
injection of a peptide from a conserved region of the MOMP
of C. trachomatis, conferred some protection against the
development of salpingitis [68]. In contrast to these findings,
Su et al. [69] found that parenteral immunization of mice
with an alum-adsorbed synthetic oligopeptide of the C.
trachomatis MOMP, was ineﬀective in preventing chlamydial
genital tract infection although mice produced high levels
of antichlamydial serum IgG neutralizing antibodies. There-
fore, DNA vaccination which induces both humoral and
cellular immune responses can be an alternative method to
protect animals from chlamydial infections.
6. DNA Vaccines—Third-Generation
C. trachomatis Vaccines
DNA immunization represents a novel approach to vaccine
and immunotherapeutic development. Injection of plasmid
DNA encoding a foreign gene of interest can result in the
subsequent expression of the foreign gene product and the
induction of an immune response within the host. DNA
vaccines have a number of advantages when compared
with alternative vaccination strategies [70]. They encode
multiple immunogenic epitopes and evoke both humoral
and cell-mediated immune responses. The immunogenic
epitopes are presented to the immune system in their native
form. Therefore, DNA vaccines exhibit the advantages of
attenuated vaccines without the safety problems associated
with the in vivo replication and possible reversion to a
virulent form. Due to the endogenous production of the
antigen, a more balanced Th1/Th2 like immune response
is elicited [71]. Plasmid vectors can be rapidly constructed
and easily tested. Large-scale manufacturing procedures are
available and the DNA can be easily and inexpensively
purified to homogeneity, resulting in lower costs to develop
and manufacture this type of vaccine [42, 72]. This makes
this strategy applicable as a human vaccine approach in
underdeveloped countries and as a veterinary vaccine strat-
egy, where the cost per dose is of major economic concern. In
addition, DNA is more thermostable than vaccine strategies
which require a cold chain for storage [73], and it should
exhibit a longer shelf-life because of the improved stability.
The production of combination vaccines employing DNA
is also simplified. DNA also allows a more simplified and
eﬀective quality control process that provides additional cost
benefits.
In addition, there are some concerns and potential
disadvantages of DNA vaccines. Firstly, the DNA could
possibly integrate into the host chromosome. This has not
been proven yet, and it is thought that the chance that
this will happen is lower than the spontaneous mutation
frequency [74]. A second concern of DNA vaccination is
the possibility of generating antibodies to DNA. Immune
responses to DNA occur in autoimmune diseases, and the
possibility exists that bacterial DNA injection could induce
an immune response that might cross-react with host DNA
[70]. Thirdly, long-term expression of injected DNA into
muscle cells may have an eﬀect on immune responses to
subsequent vaccination with diﬀerent DNA, and the immune
responses to protective epitopes associated with this second
immunization can be compromised. The fourth disadvan-
tage is that DNA vaccination strategies are unsuccessful when
evaluating non-protein-based antigens, such as bacterial
polysaccharides and lipids [70]. Other possible disadvan-
tages are the low transfection and expression eﬃciency
of DNA vaccines, certainly in large animals and humans
[75]. However, by using various combinations of delivery
systems and diﬀerent adjuvants, the immune response can
be enhanced. In the past, diﬀerent studies have evaluated
the protective potential of DNA vaccines against chlamydial
infections.
6.1. C. trachomatis DNA Vaccination. The first attempt to
generate an MOMP-based DNA vaccine against a genital
chlamydial challenge was disappointing [76]. This vaccine
encoded the MOMP gene of C. muridarum. Only modest
immune response was elicited, but no protection could
be established against infection or disease. Because DNA
immunization alone did not generate immune responses or
protection to the same extent as those induced by using
live organisms, combinational vaccines were evaluated. DNA
priming followed by boosting with immune-stimulating
complexes (ISCOM) of MOMP protein (MOMP ISCOM) in
mice resulted in higher protection when compared to mice
givenMOMP ISCOM immunization alone [77]. In 2010 and
2011, Schautteet et al. [78, 79] studied the ability of a DNA
vaccine based on C. trachomatis MOMP to protect against
genital C. trachomatis infection in a recently developed pig
model [80]. When administrating the vaccine to the vaginal
mucosa, a cellular immune response was induced which
elicited significant protection in pigs. The infection could
not be cleared completely [79]. When the DNA vaccine was
administered combined to the nasal and vaginal mucosa of
the pig, both cellular and humoral immune responses were
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induced which contributed to the significant protection of
pigs against a genital C. trachomatis infection [78].
Since a couple of years, other genes than ompA were
evaluated for their potential as vaccine candidates. DNA
immunization with the pgp3 gene of C. trachomatis could
inhibit the spread of the infection from the lower to the
upper genital tract [81]. The pgp3 gene encodes a 28 kDa
polypeptide found on the pCT plasmid of C. trachomatis
which may provide a function related to chlamydial cell
physiology [82]. Ifere et al. [83] developed a DNA vaccine
composed of MOMP and the porin B protein (PorB) of C.
trachomatis. A recombinant Vibrio Cholerae ghost (rVCG)
was used as carrier and delivery system. Significant higher
levels of Th1 response and secretory IgA and IgG2a were
induced by immunization. Furthermore, all animals which
were immunized with the multisubunit vaccine completely
resolved the infection two weeks after challenge. In 2008,
a pORF5 DNA vaccine was evaluated for its protective
immunity in a mouse model of genital chlamydial infection.
The vaccinated mice displayed significantly reduced bacterial
shedding upon chlamydial challenge and an accelerated
resolution of the infection. Furthermore, the immunized
mice also exhibited protection against pathological conse-
quences of chlamydial infection. These results demonstrate
the potential of the pORF5 DNA vaccine to elicit protective
immunity against a genital chlamydial challenge [84].
7. Impact of a C. trachomatis Vaccine
Recently, a mathematical model has been developed that
simulates transmission in a heterosexual population by
linking the within-host biology of susceptibility and the
chlamydia-infected individuals to their sexual behavior and
partnership dynamics [85]. The model tracks the infection
time course, disease progression, and dynamic infectiousness
of infected individuals and the transmission to others. The
authors have demonstrated that if a fully protective vaccine
is available, and this will be administered to adolescents
before their sexual debut, epidemics of chlamydia infection
could be eradicated within 20 years. Furthermore, it is likely
that targeting 100% of one sex (females) will have a greater
epidemiological impact than administering vaccines to 50%
of both sexes. If lifelong sterilizing immunity cannot be
achieved, a chlamydia vaccine should be eﬀective for at least
10 years in order to lead to population-level eradication.
Based on the information generated by this mathematical
model, the candidate vaccines should protect individuals by
raising the infectiousness threshold and secondary reduce the
peak load and the duration of the infection in vaccinated
individuals who become infected.
8. Conclusions
Vaccination could be substantially more eﬀective than
other biomedical interventions in controlling epidemics
of chlamydia infection. Currently, the best public health
intervention available is increasing the rate of screening
and treating infected individuals. Administrating a protective
vaccine to adolescents before their first sexual experience
could induce a significant reduction in prevalence which
could not be obtained by screening teenagers, even with
a coverage of 100% [85]. Unfortunately, no protective
vaccines, either fully or partially, are available although there
have been many attempts to develop one. The reasons for
the variability in success are still unclear but are probably
a consequence of diﬀerent immunization protocols and a
reflection of the diﬀerent protective mechanisms required for
the diﬀerent infections [55].
References
[1] WHO, Global Prevalence and Incidence of Selected Sexually
Transmitted Diseases: Overviews and Estimates, World Health
Organization, Geneva, Switzerland, 1996.
[2] C. Be´be´ar and B. de Barbeyrac, “Genital Chlamydia trachoma-
tis infections,” Clinical Microbiology and Infection, vol. 15, no.
1, pp. 4–10, 2009.
[3] R. C. Brunham and J. Rey-Ladino, “Immunology of Chlamy-
dia infection: implications for a Chlamydia trachomatis vac-
cine,” Nature Reviews Immunology, vol. 5, no. 2, pp. 149–161,
2005.
[4] J. F. Peipert, “Genital chlamydial infections,” New England
Journal of Medicine, vol. 349, no. 25, pp. 2424–2430, 2003.
[5] G. F. Gonzales, G. Mun˜oz, R. Sa´nchez et al., “Update on the
impact of Chlamydia trachomatis infection on male fertility,”
Andrologia, vol. 36, no. 1, pp. 1–23, 2004.
[6] W. E. Stamm, “Chlamydia trachomatis infections: progress and
problems,” Journal of Infectious Diseases, vol. 179, no. 2, pp.
S380–383, 1999.
[7] A. I. A. Ibrahim, A. Refeidi, and A. A. El Mekki, “Etiology and
clinical features of acute epididymo-orchitis,” Annals of Saudi
Medicine, vol. 16, no. 2, pp. 171–174, 1996.
[8] D. Taylor-Robinson and B. J. Thomas, “The role of Chlamydia
trachomatis in genital-tract and associated diseases,” Journal of
Clinical Pathology, vol. 33, no. 3, pp. 205–233, 1980.
[9] A. E. Washington and P. Katz, “Cost of and payment source
for pelvic inflammatory disease: trends and projections, 1983
through 2000,” Journal of the American Medical Association,
vol. 266, no. 18, pp. 2565–2569, 1991.
[10] L. Westrom, R. Joesoef, G. Reynolds, A. Hagdu, and S.
E. Thompson, “Pelvic inflammatory disease and fertility: a
cohort study of 1,844 women with laparoscopically verified
disease and 657 control women with normal laparoscopic
results,” Sexually Transmitted Diseases, vol. 19, no. 4, pp. 185–
192, 1992.
[11] R. J. Belland, M. A. Scidmore, D. D. Crane et al., “Chlamydia
trachomatis cytotoxicity associated with complete and partial
cytotoxin genes,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 98, no. 24, pp.
13984–13989, 2001.
[12] D. E. Nelson, D. P. Virok, H. Wood et al., “Chlamydial
IFN-γ immune evasion is linked to host infection tropism,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 102, no. 30, pp. 10658–10663, 2005.
[13] L. L. Perry, H. Su, K. Feilzer et al., “Diﬀerential sensitivity
of distinct Chlamydia trachomatis isolates to IFN-γ-mediated
inhibition,” Journal of Immunology, vol. 162, no. 6, pp. 3541–
3548, 1999.
[14] M. Johansson, K. Scho¨n, M. Ward, and N. Lycke, “Genital
tract infection with Chlamydia trachomatis fails to induce
Infectious Diseases in Obstetrics and Gynecology 7
protective immunity in gamma interferon receptor-deficient
mice despite a strong local immunoglobulin a response,”
Infection and Immunity, vol. 65, no. 3, pp. 1032–1044, 1997.
[15] J.M. Lyons, J. I. Ito, A. S. Pen˜a, and S. A.Morre´, “Diﬀerences in
growth characteristics and elementary body associated cyto-
toxicity between Chlamydia trachomatis oculogenital serovars
D and H and Chlamydia muridarum,” Journal of Clinical
Pathology, vol. 58, no. 4, pp. 397–401, 2005.
[16] I. G. M. van Valkengoed, S. A. Morre´, A. J. C. van den Brule,
C. J. L. M. Meijer, L. M. Bouter, and A. J. P. Boeke, “Over-
estimation of complication rates in evaluations of Chlamydia
trachomatis screening programmes—implications for cost-
eﬀectiveness analyses,” International Journal of Epidemiology,
vol. 33, no. 2, pp. 416–425, 2004.
[17] S. G. Morrison, C. M. Farris, G. L. Sturdevant, W. M. Whit-
mire, and R. P. Morrison, “Murine Chlamydia trachomatis
genital infection is unaltered by depletion of CD4+ T cells and
diminished adaptive immunity,” Journal of Infectious Diseases,
vol. 203, no. 8, pp. 1120–1128, 2011.
[18] R. C. Brunham, D. J. Zhang, X. Yang, and G. M. McClarty,
“The potential for vaccine development against chlamydial
infection and disease,” Journal of Infectious Diseases, vol. 181,
no. 6, pp. S538–S543, 2000.
[19] L. Hafner, K. Beagley, and P. Timms, “Chlamydia trachomatis
infection: host immune responses and potential vaccines,”
Mucosal Immunology, vol. 1, no. 2, pp. 116–130, 2008.
[20] S. A. Morre´, J. M. Lyons, J. Ito, and R. P. Morrison, “Murine
models of Chlamydia trachomatis genital tract infection: use
of mouse pneumonitis strain versus human strains,” Infection
and Immunity, vol. 68, no. 12, pp. 7209–7211, 2000.
[21] R. P. Morrison, K. Feilzer, and D. B. Tumas, “Gene knockout
mice establish a primary protective role for major histocom-
patibility complex class II-restricted responses in Chlamydia
trachomatis genital tract infection,” Infection and Immunity,
vol. 63, no. 12, pp. 4661–4668, 1995.
[22] S. G. Morrison, H. Su, H. D. Caldwell, and R. P. Morrison,
“Immunity to murine Chlamydia trachomatis genital tract
reinfection involves B cells andCD4(+) T cells but not CD8(+)
T cells,” Infection and Immunity, vol. 68, no. 12, pp. 6979–
6987, 2000.
[23] S. G. Morrison and R. P. Morrison, “Resolution of secondary
Chlamydia trachomatis genital tract infection in immunemice
with depletion of both CD4(+) and CD8(+) T cells,” Infection
and Immunity, vol. 69, no. 4, pp. 2643–2649, 2001.
[24] H. Su and H. D. Caldwell, “CD4(+) T cells play a significant
role in adoptive immunity to Chlamydia trachomatis infection
of the mouse genital tract,” Infection and Immunity, vol. 63,
no. 9, pp. 3302–3308, 1995.
[25] S. G. Morrison and R. P. Morrison, “A predominant role for
antibody in acquired immunity to chlamydial genital tract
reinfection,” Journal of Immunology, vol. 175, no. 11, pp. 7536–
7542, 2005.
[26] T.W. Cotter, K. H. Ramsey, G. S.Miranpuri, C. E. Poulsen, and
G. I. Byrne, “Dissemination of Chlamydia trachomatis chronic
genital tract infection in gamma interferon gene knockout
mice,” Infection and Immunity, vol. 65, no. 6, pp. 2145–2152,
1997.
[27] L. L. Perry, K. Feilzer, and H. D. Caldwell, “Immunity to
Chlamydia trachomatis is mediated by T helper 1 cells through
IFN-γ-dependent and -independent pathways,” Journal of
Immunology, vol. 158, no. 7, pp. 3344–3352, 1997.
[28] B. E. Batteiger, F. Xu, R. E. Johnson, and M. L. Rekart, “Pro-
tective immunity to Chlamydia trachomatis genital infection:
evidence from human studies,” Journal of Infectious Diseases,
vol. 201, supplement 2, pp. S178–S189, 2010.
[29] T. Agrawal, V. Vats, P. K. Wallace, S. Salhan, and A. Mittal,
“Cervical cytokine responses in women with primary or
recurrent chlamydial infection,” Journal of Interferon and
Cytokine Research, vol. 27, no. 3, pp. 221–226, 2007.
[30] J. N. Arno, V. A. Ricker, B. E. Batteiger, B. P. Katz, V. A. Caine,
and R. B. Jones, “Interferon-γ in endocervical secretions
of women infected with Chlamydia trachomatis,” Journal of
Infectious Diseases, vol. 162, no. 6, pp. 1385–1389, 1990.
[31] W. M. Geisler, “Duration of untreated, uncomplicated
Chlamydia trachomatis genital infection and factors associated
with chlamydia resolution: a review of human studies,” Journal
of Infectious Diseases, vol. 201, supplement 2, pp. S104–S113,
2010.
[32] T. Agrawal, V. Vats, S. Salhan, and A. Mittal, “Mucosal
and peripheral immune responses to chlamydial heat shock
proteins in women infected with Chlamydia trachomatis,”
Clinical and Experimental Immunology, vol. 148, no. 3, pp.
461–468, 2007.
[33] S. Ghaem-Maghami, G. Ratti, M. Ghaem-Maghami et al.,
“Mucosal and systemic immune responses to plasmid protein
pgp3 in patients with genital and ocular Chlamydia trachoma-
tis infection,” Clinical and Experimental Immunology, vol. 132,
no. 3, pp. 436–442, 2003.
[34] M. S. Pate, S. R. Hedges, D. A. Sibley, M. W. Russell, E.
W. Hook, and J. Mestecky, “Urethral cytokine and immune
responses in Chlamydia trachomatis-infected males,” Infection
and Immunity, vol. 69, no. 11, pp. 7178–7181, 2001.
[35] J.Mestecky, Z.Moldoveanu, andM.W.Russell, “Immunologic
uniqueness of the genital tract: challenge for vaccine develop-
ment,” American Journal of Reproductive Immunology, vol. 53,
no. 5, pp. 208–214, 2005.
[36] E. L. Johansson, L. Wasse´n, J. Holmgren, M. Jertborn, and A.
Rudin, “Nasal and vaginal vaccinations have diﬀerential eﬀects
on antibody responses in vaginal and cervical secretions in
humans,” Infection and Immunity, vol. 69, no. 12, pp. 7481–
7486, 2001.
[37] P. A. Kozlowski, S. B.Williams, R. M. Lynch et al., “Diﬀerential
induction of mucosal and systemic antibody responses in
women after nasal, rectal, or vaginal immunization: influence
of the menstrual cycle,” Journal of Immunology, vol. 169, no. 1,
pp. 566–574, 2002.
[38] S. Van Drunen Littel-Van Den Hurk, V. Gerdts, B. I. Loehr
et al., “Recent advances in the use of DNA vaccines for the
treatment of diseases of farmed animals,” Advanced Drug
Delivery Reviews, vol. 43, no. 1, pp. 13–28, 2000.
[39] R. C. Brunham, D. J. Zhang, X. Yang, and G. M. McClarty,
“The potential for vaccine development against chlamydial
infection and disease,” Journal of Infectious Diseases, vol. 181,
no. 6, supplement 3, pp. S538–S543, 2000.
[40] A. J. Stagg, “Vaccines against Chlamydia: approaches and
progress,”MolecularMedicine Today, vol. 4, no. 4, pp. 166–173,
1998.
[41] P. E. Shewen, R. C. Povey, andM. R. Wilson, “A comparison of
the eﬃcacy of a live and four inactivated vaccine preparations
for the protection of cats against experimental challenge
with Chlamydia psittaci,” Canadian Journal of Comparative
Medicine, vol. 44, no. 3, pp. 244–251, 1980.
[42] D. Longbottom and M. Livingstone, “Vaccination against
chlamydial infections of man and animals,”Veterinary Journal,
vol. 171, no. 2, pp. 263–275, 2006.
[43] E. M. Peterson, J. Z. You, V. Motin, and L. M. De La
Maza, “Intranasal immunization with Chlamydia trachomatis,
8 Infectious Diseases in Obstetrics and Gynecology
serovar E, protects from a subsequent vaginal challenge with
the homologous serovar,” Vaccine, vol. 17, no. 22, pp. 2901–
2907, 1999.
[44] H. Su, R. Messer, W. Whitmire, S. Hughes, and H. D.
Caldwell, “Subclinical chlamydial infection of the female
mouse genital tract generates a potent protective immune
response: implications for development of live attenuated
chlamydial vaccine strains,” Infection and Immunity, vol. 68,
no. 1, pp. 192–196, 2000.
[45] N. Olivares-Zavaleta, W. Whitmire, D. Gardner, and H. D.
Caldwell, “Immunization with the attenuated plasmidless
Chlamydia trachomatis L2(25667R) strain provides partial
protection in a murine model of female genitourinary tract
infection,” Vaccine, vol. 28, no. 6, pp. 1454–1462, 2010.
[46] H. Yu, K. P. Karunakaran, I. Kelly et al., “Immunization
with live and dead Chlamydia muridarum induces diﬀerent
levels of protective immunity in a murine genital tract model:
correlation with MHC class II peptide presentation and
multifunctional Th1 cells,” Journal of Immunology, vol. 186,
no. 6, pp. 3615–3621, 2011.
[47] C. Olive, I. Toth, and D. Jackson, “Technological advances in
antigen delivery and synthetic peptide vaccine developmental
strategies,” Mini Reviews in Medicinal Chemistry, vol. 1, no. 4,
pp. 429–438, 2001.
[48] J. Hess, U. Schaible, B. Raupach, and S. H. E. Kaufmann,
“Exploiting the immune system: toward new vaccines against
intracellular bacteria,” Advances in Immunology, vol. 75, pp. 1–
88, 2000.
[49] H. D. Caldwell, J. Kromhout, and J. Schachter, “Purification
and partial characterization of the major outer membrane
protein of Chlamydia trachomatis,” Infection and Immunity,
vol. 31, no. 3, pp. 1161–1176, 1981.
[50] S. Pal, I. Theodor, E. M. Peterson, and L. M. De la Maza,
“Immunization with an acellular vaccine consisting of the
outer membrane complex of Chlamydia trachomatis induces
protection against a genital challenge,” Infection and Immu-
nity, vol. 65, no. 8, pp. 3361–3369, 1997.
[51] S. Pal, I. Theodor, E. M. Peterson, and L. M. De la Maza,
“Immunization with the Chlamydia trachomatis mouse pneu-
monitis major outer membrane protein can elicit a protective
immune response against a genital challenge,” Infection and
Immunity, vol. 69, no. 10, pp. 6240–6247, 2001.
[52] C. Cheng, I. Bettahi, M. I. Cruz-Fisher et al., “Induction of
protective immunity by vaccination against Chlamydia tra-
chomatis using the major outer membrane protein adjuvanted
with CpG oligodeoxynucleotide coupled to the nontoxic B
subunit of cholera toxin,” Vaccine, vol. 27, no. 44, pp. 6239–
6246, 2009.
[53] K. A. Cunningham, A. J. Carey, L. Hafner, P. Timms, and K.
W. Beagley, “Chlamydia muridarum major outer membrane
protein-specific antibodies inhibit in vitro infection but
enhance pathology in vivo,” American Journal of Reproductive
Immunology, vol. 65, no. 2, pp. 118–126, 2011.
[54] J. U. Igietseme and A. Murdin, “Induction of protective
immunity against Chlamydia trachomatis genital infection
by a vaccine based on major outer membrane protein-
lipophilic immune response-stimulating complexes,” Infection
and Immunity, vol. 68, no. 12, pp. 6798–6806, 2000.
[55] D. Longbottom, “Chlamydial vaccine development,” Journal of
Medical Microbiology, vol. 52, no. 7, pp. 537–540, 2003.
[56] C. Escalante-Ochoa, R. Ducatelle, and F. Haesebrouck, “The
intracellular life of Chlamydia psittaci: how do the bacteria
interact with the host cell?” FEMS Microbiology Reviews, vol.
22, no. 2, pp. 65–78, 1998.
[57] A. F. Swanson and C. C. Kuo, “Evidence that the major outer
membrane protein of Chlamydia trachomatis is glycosylated,”
Infection and Immunity, vol. 59, no. 6, pp. 2120–2125, 1991.
[58] L. J. Berry, D. K. Hickey, K. A. Skelding et al., “Transcuta-
neous immunization with combined cholera toxin and CpG
adjuvant protects against Chlamydia muridarum genital tract
infection,” Infection and Immunity, vol. 72, no. 2, pp. 1019–
1028, 2004.
[59] S. Pal, C. J. Luke, A. G. Barbour, E. M. Peterson, and L. M.
De La Maza, “Immunization with the Chlamydia trachomatis
major outer membrane protein, using the outer surface
protein A of Borrelia burgdorferi as an adjuvant, can induce
protection against a chlamydial genital challenge,”Vaccine, vol.
21, no. 13-14, pp. 1455–1465, 2003.
[60] G. Sun, S. Pal, J. Weiland, E. M. Peterson, and L. M. de la
Maza, “Protection against an intranasal challenge by vaccines
formulated with native and recombinant preparations of
the Chlamydia trachomatis major outer membrane protein,”
Vaccine, vol. 27, no. 36, pp. 5020–5025, 2009.
[61] D. K. Hickey, F. E. Aldwell, and K. W. Beagley, “Transcu-
taneous immunization with a novel lipid-based adjuvant
protects against Chlamydia genital and respiratory infections,”
Vaccine, vol. 27, no. 44, pp. 6217–6225, 2009.
[62] P. Ralli-Jain, D. Tifrea, C. Cheng, S. Pal, and L. M. de la
Maza, “Enhancement of the protective eﬃcacy of a Chlamydia
trachomatis recombinant vaccine by combining systemic and
mucosal routes for immunization,”Vaccine, vol. 28, no. 48, pp.
7659–7666, 2010.
[63] M. Tuﬀrey, F. Alexander, W. Conlan, C. Woods, and M.
Ward, “Heterotypic protection of mice against chlamydial
salpingitis and colonization of the lower genital tract with a
human serovar F isolate of Chlamydia trachomatis by prior
immunization with recombinant serovar L1 major outer-
membrane protein,” Journal of General Microbiology, vol. 138,
no. 8, pp. 1707–1715, 1992.
[64] A. K. Murthy, J. P. Chambers, P. A. Meier, G. Zhong, and
B. P. Arulanandam, “Intranasal vaccination with a secreted
chlamydial protein enhances resolution of genital Chlamydia
muridarum infection, protects against oviduct pathology, and
is highly dependent upon endogenous gamma interferon
production,” Infection and Immunity, vol. 75, no. 2, pp. 666–
676, 2007.
[65] F. Follmann, A. W. Olsen, K. T. Jensen, P. R. Hansen, P.
Andersen, and M. Theisen, “Antigenic profiling of a Chlamy-
dia trachomatis gene-expression library,” Journal of Infectious
Diseases, vol. 197, no. 6, pp. 897–905, 2008.
[66] A. W. Olsen, F. Follmann, K. Jensen et al., “Identification
of CT521 as a frequent target of Th1 cells in patients
with urogenital Chlamydia trachomatis infection,” Journal of
Infectious Diseases, vol. 194, no. 9, pp. 1258–1266, 2006.
[67] D. K. Hickey, F. E. Aldwell, and K. W. Beagley, “Oral
immunization with a novel lipid-based adjuvant protects
against genital Chlamydia infection,” Vaccine, vol. 28, no. 7,
pp. 1668–1672, 2010.
[68] S. C. Knight, S. Iqball, C. Woods, A. Stagg, M. E. Ward, and
M. Tuﬀrey, “A peptide of Chlamydia trachomatis shown to
be a primary T-cell epitope in vitro induces cell-mediated
immunity in vivo,” Immunology, vol. 85, no. 1, pp. 8–15, 1995.
[69] H. Su, M. Parnell, and H. D. Caldwell, “Protective eﬃcacy of a
parenterally administered MOMP-derived synthetic oligopep-
tide vaccine in a murine model of Chlamydia trachomatis
genital tract infection: serum neutralizing IgG antibodies do
not protect against chlamydial genital tract infection,”Vaccine,
vol. 13, no. 11, pp. 1023–1032, 1995.
Infectious Diseases in Obstetrics and Gynecology 9
[70] A. M. Watts and R. C. Kennedy, “DNA vaccination strategies
against infectious diseases,” International Journal for Parasitol-
ogy, vol. 29, no. 8, pp. 1149–1163, 1999.
[71] J. B. Ulmer, T. M. Fu, R. R. Deck et al., “Protective CD4(+) and
CD8(+) T cells against influenza virus induced by vaccination
with nucleoprotein DNA,” Journal of Virology, vol. 72, no. 7,
pp. 5648–5653, 1998.
[72] V. Dufour, “DNA vaccines: new applications for veterinary
medicine,” Veterinary Sciences Tomorrow, vol. 1, pp. 1–19,
2001.
[73] H. C. J. Ertl and Z. Q. Xiang, “Genetic immunization,” Viral
Immunology, vol. 9, no. 1, pp. 1–9, 1996.
[74] T. Martin, S. E. Parker, R. Hedstrom et al., “Plasmid DNA
malaria vaccine: the potential for genomic integration after
intramuscular injection,” Human Gene Therapy, vol. 10, no.
5, pp. 759–768, 1999.
[75] L. A. Babiuk, R. Pontarollo, S. Babiuk, B. Loehr, and S. Van
Drunen Littel-van denHurk, “Induction of immune responses
by DNA vaccines in large animals,”Vaccine, vol. 21, no. 7-8, pp.
649–658, 2003.
[76] S. Pal, K. M. Barnhart, Q.Wei, A. M. Abai, E. M. Peterson, and
L. M. De La Maza, “Vaccination of mice with DNA plasmids
coding for the Chlamydia trachomatis major outer membrane
protein elicits an immune response but fails to protect against
a genital challenge,” Vaccine, vol. 17, no. 5, pp. 459–465, 1999.
[77] D. J. Zhang, X. Yang, C. Shen, H. Lu, A. Murdin, and R.
C. Brunham, “Priming with Chlamydia trachomatis major
outer membrane protein (MOMP) DNA followed by MOMP
ISCOM boosting enhances protection and is associated with
increased immunoglobulin A and Th1 cellular immune
responses,” Infection and Immunity, vol. 68, no. 6, pp. 3074–
3078, 2000.
[78] K. Schautteet, Epidemiological Research on Chlamydiaceae in
Pigs and Evaluation of a Chlamydia trachomatis DNA vaccine,
Ghent University, Ghent, Belgium, 2010.
[79] K. Schautteet, E. Stuyven, D. S. A. Beeckman et al., “Pro-
tection of pigs against Chlamydia trachomatis challenge by
administration of a MOMP-based DNA vaccine in the vaginal
mucosa,” Vaccine, vol. 29, no. 7, pp. 1399–1407, 2011.
[80] D. Vanrompay, T. Q. T. Hoang, L. De Vos et al., “Specific-
pathogen-free pigs as an animalmodel for studyingChlamydia
trachomatis genital infection,” Infection and Immunity, vol. 73,
no. 12, pp. 8317–8321, 2005.
[81] M. Donati, V. Sambri, M. Comanducci et al., “DNA immu-
nization with pgp3 gene of Chlamydia trachomatis inhibits the
spread of chlamydial infection from the lower to the upper
genital tract in C3H/HeN mice,” Vaccine, vol. 21, no. 11-12,
pp. 1089–1093, 2003.
[82] M. Comanducci, R. Cevenini, A. Moroni et al., “Expression of
a plasmid gene of Chlamydia trachomatis encoding a novel 28
kDa antigen,” Journal of General Microbiology, vol. 139, no. 5,
pp. 1083–1092, 1993.
[83] G. O. Ifere, Q. He, J. U. Igietseme et al., “Immunogenicity
and protection against genital Chlamydia infection and its
complications by a multisubunit candidate vaccine,” Journal
of Microbiology, Immunology and Infection, vol. 40, no. 3, pp.
188–200, 2007.
[84] Z. Li, S.Wang, Y. Wu, G. Zhong, and D. Chen, “Immunization
with chlamydial plasmid protein pORF5 DNA vaccine induces
protective immunity against genital chlamydial infection in
mice,” Science in China C, vol. 51, no. 11, pp. 973–980, 2008.
[85] R. T. Gray, K. W. Beagley, P. Timms, and D. P. Wilson,
“Modeling the impact of potential vaccines on epidemics
of sexually transmitted Chlamydia trachomatis infection,”
Journal of Infectious Diseases, vol. 199, no. 11, pp. 1680–1688,
2009.
